Massachusetts-based iVexSol has secured funding to the tune of $23.8 million in its latest Series A round. The new investors include Bristol Myers Squibb, manufacturer Charles River Laboratories and Asahi Kasei Medical. iVexSol is a manufacturer of lentiviral vectors (LVV), used in making gene therapies, and this latest round of…
News Ticker
- [ March 27, 2023 ] CSL Opens New, State-of-the-Art Vaccine Research and Development Facility in Waltham, Massachusetts News
- [ March 27, 2023 ] Research Scientist, AAV Cell & Gene Therapy – Novartis Argentina – Cambridge, MA Jobs
- [ March 27, 2023 ] Research Scientist, Discovery & Translational Pharmacology – Novartis Argentina – Cambridge, MA Jobs
- [ March 27, 2023 ] Senior Scientist, Innovative Lentiviral Vector Design (BS/MS) – Novartis Argentina – Cambridge, MA Jobs
- [ March 27, 2023 ] Senior Scientist –Sickle Cell Disease; Hematology – Novartis Argentina – Cambridge, MA Jobs
Copyright © 2022 Biotech Networks, LLC
